Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

Inclusion Criteria: \- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis. Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab. Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients. Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent. Exclusion Criteria: \- Those who are unable to complete at least one month follow-up based on the investigator's judgment. Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits. Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding. Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.